Development of an optimized and generic cost-utility model for analyzing genome-guided treatment data

Pandi, Maria‐Theodora; Koromina, Maria; Vonitsanos, Gerasimos; Spek, Peter J. van der; Patrinos, George P.; Mitropoulou, Christina

doi:10.1016/j.phrs.2022.106187

Cited by 2 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, economic calculations are highly sensitive to healthcare system‐specific parameters and, thus, require resource‐intensive modelling efforts for each country separately. However, recently developed generic models hold promise to facilitate such analyses 78 . To date, no trials have been published that evaluate the cost‐effectiveness of pharmacogenomic sequencing outside of oncology.…”

Section: Implementation and Precision Medicinementioning

confidence: 99%

“…However, recently developed generic models hold promise to facilitate such analyses. 78 To date, no trials have been published that evaluate the cost‐effectiveness of pharmacogenomic sequencing outside of oncology. Prospective clinical trials that evaluate the cost‐effectiveness of NGS coupled to computational variant predictions are thus of critical importance to provide patient benefits without overburdening the healthcare system.…”

Section: Implementation and Precision Medicinementioning

confidence: 99%

See 1 more Smart Citation

A paradigm shift in pharmacogenomics: From candidate polymorphisms to comprehensive sequencing

Zhou

Koutsilieri

Eliasson

et al. 2022

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Genetic factors have long been recognized as important determinants of interindividual variability in drug efficacy and toxicity. However, despite the increasing number of established gene-drug associations, candidate polymorphisms can only explain a fraction of the genetically encoded functional variability in drug disposition. Advancements in genetic profiling methods now allow to analyse the landscape of human pharmacogenetic variations comprehensively, which opens new opportunities to identify novel factors that could explain the "missing heritability." Here, we provide an updated overview of the landscape of pharmacogenomic variability based on recent analyses of population-scale sequencing projects. We then summarize the current state-of-the-art how the functional consequences of variants with unknown effects can be quantitatively estimated while discussing challenges and peculiarities that are specific to pharmacogenes. In the last sections, we discuss the importance of considering ethnogeographic diversity to provide equitable benefits of pharmacogenomics and summarize current roadblocks for the implementation of sequencing-based guidance of clinical decision-making.Based on the current state of the field, we conclude that testing is likely to gradually shift from the interrogation of selected candidate polymorphisms to comprehensive sequencing, which allows to consider the full spectrum of pharmacogenomic variations for a true personalization of genomic prescribing.

show abstract

Section: Implementation and Precision Medicinementioning

confidence: 99%

Section: Implementation and Precision Medicinementioning

confidence: 99%

A paradigm shift in pharmacogenomics: From candidate polymorphisms to comprehensive sequencing

Zhou

Koutsilieri

Eliasson

et al. 2022

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

Assessing the Utility of Measurement Methods Applied in Economic Evaluations of Pharmacogenomics Applications

Fragoulakis,

Koufaki,

Tzerefou

et al. 2024

Pharmacogenomics

View full text Add to dashboard Cite

An increasing number of economic evaluations are published annually investigating the economic effectiveness of pharmacogenomic (PGx) testing. This work was designed to provide a comprehensive summary of the available utility methods used in cost–effectiveness/cost-utility analysis studies of PGx interventions. A comprehensive review was conducted to identify economic analysis studies using a utility valuation method for PGx testing. A total of 82 studies met the inclusion criteria. A majority of studies were from the USA and used the EuroQol-5D questionnaire, as the utility valuation method. Cardiovascular disorders was the most studied therapeutic area while discrete-choice studies mainly focused on patients' willingness to undergo PGx testing. Future research in applying other methodologies in PGx economic evaluation studies would improve the current research environment and provide better results.

show abstract

Development of an optimized and generic cost-utility model for analyzing genome-guided treatment data

Cited by 2 publications

References 24 publications

A paradigm shift in pharmacogenomics: From candidate polymorphisms to comprehensive sequencing

A paradigm shift in pharmacogenomics: From candidate polymorphisms to comprehensive sequencing

Assessing the Utility of Measurement Methods Applied in Economic Evaluations of Pharmacogenomics Applications

Contact Info

Product

Resources

About